A placebo-controlled phase III trial (ONO-4538-52/TASUKI-52) was conducted to evaluate the superiority of nivolumab plus carboplatin plus paclitaxel plus bevacizumab over carboplatin plus paclitaxel plus bevacizumab in patients with advanced non-squamous NSCLC and PD-L1 expression of ≥1%; the median PFS times were 12.1 months (96.37% CI, 9.8–14.0) and 8.1 months (96.37% CI, 7.0–8.5), respectively, with an HR of 0.56 (96.4% CI, 0.43–0.71; p < 0.0001), with significantly better outcomes in the nivolumab arm regardless of tumor PD-L1 expression status (102). The gene discussed is CD274; the disease is neoplasm.